Muscle strength is assumed to be closely related with BMD, the so called determinant of bone strength, however, new methods for bone strength measurement are arising. The purpose of this study was to determine the relationship between bone mineral density (BMD), muscle strength and natural frequency of the radius in the dominant and non-dominant arm in healthy and osteopenic individuals aged between 50-70 years. Sixty sedentary male (thirty healthy and thirty osteopenic) participated this study. Bone mineral density assessment was performed by dual x-ray absorbtiometry (DEXA) and quantitative computed tomography (QCT), whereas muscle strength was measured by an isokinetic dynamometer quantitatively. Natural frequency of the radius was determined by a dual channel frequency analyzer. Differences between BMD, muscle strength and natural frequency in healthy and osteopenic participants according to dominancy were examined by Analysis of Variance (ANOVA). Pearson Product Correlation Coefficient test was conducted to determine the magnitude of the correlation between cortical, trabecular and average BMD, muscle strength and natural frequency. Results demonstrated a statistically significant difference between BMD, natural frequency and muscle strength in the dominant arm of both groups. There was also a significant difference in the non-dominant arm in terms of BMD, natural frequency and muscle strength, except in total work in the non-dominant arms. Moreover, there was a moderate positive correlation between BMD measured by DEXA and natural frequency in the dominant arm (r = ,59 / p &lt / .001) and non-dominant arm (r = 0,64 / p &lt / 0.001), whereas the muscle strength was correlated to BMD with a low positive correlation in terms of peak torque in extension (r = ,36 / p = ,005), peak torque in flexion (r = ,31 / p = ,016), total work in extension (r = ,28 / p = ,030) and total work in flexion (r = ,27 / p = ,041) in the dominant arms. The correlation between muscle strength and BMD was not significant in the non-dominant arm. The highest correlation between natural frequency and bone geometry parameters was observed in cortical thickness (r = ,82 / p = ,02). A statistically significant positive correlation (r = ,81 / p = ,04) was also observed between average BMD measured by QCT and by DEXA. In summary, according to the findings of this study, it can be concluded that vibration analysis is a precise method in predicting bone strength that depends highly on its size, shape and the distribution of its trabecular and cortical components.

Determination of body composition or amount and decomposition of body fat belongs to the basic clinical examination of an obese patient. But methods used to determine the amount of fat in obese population are often innacurate. And it's adipose tissue and its measurable parameters which can provide us range of information for the further process of the reductive treatment. The main goal of this work is to evaluate the physiological aspects of body composition measurement in several areas: (I) To determine whether the values of body fat measured by most commonly used methods are comparable to those measured by method DEXA. (II) To determine whether the values of the amount of body fat measured by different methods vary depending on the amount of BMI and adipose tissue in the body and assess whether the available bioimpendance methods can measure the functional state of body fat. (III) To assess the resting energy expenditure in relation to body composition and physical activity. (IV) To determine whether the body composition will affect the resulting reduction after excercise program for women with overweight and obesity. (V) To verify whether changes in the values of BOHB (Beta Hydroxybutyrate) after physical activity could be the predictor of weight losses and changes of body composition. Based on...

Objective: To investigate the extent to which changes in physical activity predict changes in abdominal fat in women over an 18-month period, while statistically controlling the effects of possible confounders, such as age, total body fat percent, and energy intake. Design: A prospective cohort design over 18 months. There was no intervention or treatment. Changes in objectively-measured physical activity were used to predict changes in abdominal fat over the study period. Subjects: 110 healthy, middle-aged women (mean: 41.3±3.3 yrs), primarily Caucasian, educated, and married. Measurements: An objective measure of physical activity (ACT) using CSA accelerometers, worn continuously for 7 consecutive days at baseline and again at follow-up. Total body fat and abdominal fat percent were assessed by dual energy x-ray absorptiometry (DEXA). Energy intake was estimated using 7-day, weighed food records for the days in which subjects wore accelerometers. Results: No significant change between baseline and follow-up means for abdominal fat, physical activity, or energy intake over the study period. Moreover, change in physical activity was not a significant predictor of change in abdominal fat, with or without statistical control of confounders. Change in energy intake was a predictor of abdominal fat (P=0.0688), and this association was strengthened after adjusting for age, baseline total body fat, and changes in physical activity. Conclusions: Apparently, when measured using accelerometers, changes in physical activity are not predictive of changes in abdominal fat over an 18-month period. However, changes in energy intake seem to predict changes in abdominal fat. Evidently, increases and decreases in abdominal fat are more a function of energy intake than physical activity in middle-aged women.

In recent years, the intermittent, exogenous application of parathyroid hormone fragment has been established as a therapeutic agent for human osteoporosis. The present placebo-controlled trial evaluated the effects of intermittent, exogenous application of equine parathyroid hormone fragment (ePTH 1-37) on calcium homeostasis and bone metabolism in healthy horses. The dose-response relationship and an appropriate daily treatment scheme with ePTH (1-37) were assessed with 0.5, 1, 5, 10, and 40 µg ePTH (1-37)/kg BW to provide a basis for long-term ePTH (1-37) application. The dose selection of 0.5 µg ePTH (1-37)/kg KM for long-term application resulted from a short, temporary increase in the ionized blood calcium level after ePTH (1-37) injection and an unimpaired fractional calcium and phosphorus excretion. Higher dosages caused adverse events such as persisting hypercalcemia and general condition disturbance after 2 or 3 days of treatment. In a subsequent attempt, 6 horses each received either ePTH (1-37) or placebo for 120 days by daily subcutaneous injections. The diurnal response of calcium in blood reflected the responsiveness of the target cells to exogenous application of ePTH (1-37). During the observation period, cancellous bone mineral density increased significantly, but showed no differences between ePTH treatment and placebo. After long-term application, parathyroid response and endogenous intact parathyroid hormone release were investigated using Na2EDTA-induced hypocalcemia. Previously ePTH-treated horses showed moderately reduced levels of endogenous intact PTH when compared to those results obtained in the placebo group. Concomitant, ePTH-treated horses appeared to have a more rapid and improverd recovery of calcium homeostasis. In general, the long-term intermittent application of 0.5 µg ePTH (1-37)/kg BW seemed to have no negative effects in healthy horses. The potential area of ePTH application in horses could be osteoporotic stages, for instance, as observed in podotrochlosis and glucocorticoid-induced bone loss.

In recent years, the intermittent, exogenous application of parathyroid hormone fragment has been established as a therapeutic agent for human osteoporosis. The present placebo-controlled trial evaluated the effects of intermittent, exogenous application of equine parathyroid hormone fragment (ePTH 1-37) on calcium homeostasis and bone metabolism in healthy horses. The dose-response relationship and an appropriate daily treatment scheme with ePTH (1-37) were assessed with 0.5, 1, 5, 10, and 40 µg ePTH (1-37)/kg BW to provide a basis for long-term ePTH (1-37) application. The dose selection of 0.5 µg ePTH (1-37)/kg KM for long-term application resulted from a short, temporary increase in the ionized blood calcium level after ePTH (1-37) injection and an unimpaired fractional calcium and phosphorus excretion. Higher dosages caused adverse events such as persisting hypercalcemia and general condition disturbance after 2 or 3 days of treatment. In a subsequent attempt, 6 horses each received either ePTH (1-37) or placebo for 120 days by daily subcutaneous injections. The diurnal response of calcium in blood reflected the responsiveness of the target cells to exogenous application of ePTH (1-37). During the observation period, cancellous bone mineral density increased significantly, but showed no differences between ePTH treatment and placebo. After long-term application, parathyroid response and endogenous intact parathyroid hormone release were investigated using Na2EDTA-induced hypocalcemia. Previously ePTH-treated horses showed moderately reduced levels of endogenous intact PTH when compared to those results obtained in the placebo group. Concomitant, ePTH-treated horses appeared to have a more rapid and improverd recovery of calcium homeostasis. In general, the long-term intermittent application of 0.5 µg ePTH (1-37)/kg BW seemed to have no negative effects in healthy horses. The potential area of ePTH application in horses could be osteoporotic stages, for instance, as observed in podotrochlosis and glucocorticoid-induced bone loss.

No description available.

L'ischémie/reperfusion (I/R) est un phénomène très fréquent en clinique humaine. Ce phénomène est observé lors de la désobstruction d'une artère digestive, du traitement d'un état de choc, ainsi qu'au cours d'autres pathologies. L'interruption de la perfusion tissulaire (ischémie) et le rétablissement de celle-ci (reperfusion) sont la cause de la mise en place de troubles hémodynamiques et métaboliques. L'I/R est souvent présentée comme étant la principale source de l'hyperlactatémie et le moteur de la réponse inflammatoire lors des états de choc (cardiogénique, hypovolémique, septique). Parallèlement, elle est responsable de l'induction de la production de la libération des espèces réactives de l'oxygène, des cytokines et du monoxyde d'azote. Suite à un choc hémorragique par Ischémie/reperfusion chez le rat, nous avons montré que 1) le NaHS, donneur d'H2S limite la diminution de la pression artérielle moyenne et diminue le lactate plasmatique, témoin de la souffrance tissulaire, 2) cette amélioration hémodynamique est associée à une baisse de l'expression myocardique des ARNm d'iNOS, une diminution de la concentration des dérivés NOx plasmatiques et une diminution des concentrations aortiques et myocardiques de NO et d'anion superoxyde et 3) l'inhibition d'H2S par la DL-propargylglycine aggrave le tableau hémodynamique et les conséquences tissulaires du choc. Dans un autre modèle d'ischémie/reperfusion intestinale, les résultats obtenus, montrent que l'administration de la Protéine C activée (PCa) ou de la dexaméthaosne (Dexa) : 1) améliore la PAM et la réactivité vasculaire, 2) permet d'augmenter le pH et de diminuer la lactatémie, 3) diminue la production des cytokines pro-inflammatoires et 4) inhibe les médiateurs de l'apoptose. Ces résultats sont reliés à une down régulation d'iNOS, une restauration de la voie Akt/eNOS et à une resensibilisation des adrénorécepteurs alpha. Ces résultats ouvrent de nouvelles perspectives cliniques dans les traitements de l'I/R / Ischemia/reperfusion (I/R) is a very common phenomenon, observed during intestinal artery surgery, shock treatment, as well as in several other diseases. The disruption of tissue perfusion (ischemia) and recovery (reperfusion) induce hemodynamic and metabolic dysfunction. Gut ischemia/reperfusion is often presented as the main source of lactate and the motor of the inflammatory response, such as cardiogenic, hypovolemic and septic shock. In parallel, gut reperfusion produces numerous mediators such as reactive oxygen metabolites, pro-inflammatory cytokines, and high concentrations of nitric oxide. In a model of ischemia/reperfusion induced by hemorrhagic shock, we found that 1) NaHS an injectable form of H2S, limited the decrease in arterial pressure induced by shock and decreased plasmatic lactate, a witness of tissue suffering, 2) this hemodynamic improvement was associated with a fall in myocardial iNOS mRNA expression, a reduction in the concentration of plasmatic NOx and a reduction of aortic and myocardial concentrations of NO and superoxide anion and 3) the inhibition of H2S with DL-propargylglycine worsened hemodynamics and tissue consequences of shock An experimental model of intestinal I/R has been developed, we demonstrated that the administration of APC or Dexa : 1) Improves MAP and vascular reactivity, 2) increased pH and decreased lactate, 3) decreased pro-inflammatory cytokines production and 4) inhibited apoptosis mediators expression. These results are related to a down regulation of iNOS, to a restoration of the AKT/eNOS pathway, and to alpha-adrenoreceptor resensitization. These results open new perspectives in clinical treatment of I/R

No description available.

In order to elucidate the effects of NPY directly on bone tissue, two different doses of NPY (NPY dose 1= 1X10-5 M and NPY dose 2 = 1X 10&amp / #65533 / 6 M) and NPY dose 2 plus its inhibitor were applied together with hyaluronic acid (HA) into the intramedullary area of right tibia of Wistar rats. HA alone was administered as the control group. On three time points, day one, week one and week two after administration, the tibiae were collected and stored at &amp / #65533 / 20oC for analysis. Evaluation was performed via conventional radiography, dual energy X-ray absorbtiometry (DEXA), quantitative computerized tomography (QCT), three point bending test (TPB) and histology techniques. QCT was used to assess both atomic content and density of both medulla and cortex of tibiae. From DEXA results, it was observed that inhibition of NPY causes an increase in the bone mass from first day to second week. This phenomena was also observed in histology results so that new bone formation in the inhibitor administered bone was encountered at week two. In both medulla and cortex areas&amp / #65533 / atomic content, an increase in average effective atomic number was displayed after administration of NPY plus NPY inhibitor throughout two weeks. In addition, density of medulla of tibiae measured by QCT also revealed an increase in bone mass when inhibitor is applied throughout two weeks. As a result, overall evaluation of data obtained from DEXA, QCT and histological analysis revealed that NPY inhibits bone formation or have a pro-osteoclastic effect / inversely HA displayed osteogenic effect.

Title: Body composition in patients with idiopatic inflammatory myopathies Objectives: The aim of this study was to compare selected parameters of body composition in patients with idiopathic inflammatory myopathies (IIM) with age- and sex-matched healthy controls (HC). Another objective was to evaluate the effect of selected clinical parameters in patients with IIM on the detectedvariability of the parameters of body composition and on physical activity of patients. Methods: The research sample consisted of 84 individuals (54 IIM, 30 HC). In anthropometry, we measured: body height (cm), weight (kg) and BMI (kg/m2 ). Using bioelectrical impedance analysis BIA 2000-M we obtained values: total body water (TBW in%), muscle mass (LBM in kg), body fat (BF in%) cell mass of lean body mass (BCM of FFM in%), and the proportion of extracellular/intracellular matrix (ECM/BCM). Using Lunar series iDXA we obtained values: muscle mass (LBM in kg), body fat (BF in %), bone mineral density (BMD in g/cm3 ), and visceral fat (Visceral in kg). To these measured values we added a questionnaire on physical activity Human Acitvity Profile (HAP). Statistics: T-test, Mann Whitney U test, Cohen's d, and Partialeta-squared. Results: Selected values (mean ± SD): body height: IIM 164.7 ± 9.1 cm, HC 170.3 ± 7 cm; body weight:...